CRISPR/Cas9-Mediated Knock-In of BRCA1/2 Mutations Restores Response to Olaparib in Pancreatic Cancer Cell Lines

Scientists induced BRCA1 and BRCA2 mutations in PDAC cell-lines using a clustered regularly interspaced short palindromic repeats (CRISPR)/associated protein 9 (Cas9)-mediated knock-in technology.